Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Revlimid Offers Great Convenience: Dr Hatake of Cancer Institute Hospital
August 29, 2011
- US Court of Appeals Rules for MTPC in Argatroban Patent Dispute
August 29, 2011
- No. of Health Insurance Societies That Report Savings by Generics to Insured More Than Triples: Kenporen
August 29, 2011
- Launching of Novel Anticoagulants Welcomed: JCS Symposium
August 29, 2011
- Radioactive Cesium Detected from RDF Incineration Ashes at Chugai's Research Lab
August 29, 2011
- St. Marianna Univ. Hospital Group Saves over ¥600 Mil. in Drug Expenditures by Using Generics
August 29, 2011
- Takeda to Increase No. of MRs to 2,000 in China
August 29, 2011
- Concrete Disclosure Standards Should Have Been Included in JPMA's GLs for COI: Prof. Miyata
August 29, 2011
- Eisai Subsidiary's CT Colonography System Receives Approval in Japan
August 29, 2011
- Actos Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
August 29, 2011
- Korosho to Grant Subsidies to 4 Companies to Develop, Manufacture New Flu Vaccines
August 29, 2011
- Use Medicoeconomic Evaluation in NHI Drug Pricing: Korosho Study Group
August 29, 2011
- Novartis Pharma to Ask Korosho Why It Was Not Selected for Vaccine Grant
August 29, 2011
- Korosho Orders Revision of Package Insert, “Blue Letter”for Prazaxa after 5 Deaths
August 29, 2011
- NanoCarrier Ties Up with Kyoto Univ. for Nucleic Acid Drugs
August 29, 2011
- AZ Aims to Make Nexium the No. 1 PPI in Japan
August 29, 2011
- Celsentri Approved for Naive HIV-Infected Patients: ViiV Healthcare
August 29, 2011
- AnGes MG to Jointly Develop Therapeutic HPV Vaccine with GenoLac
August 29, 2011
- NBI Increasing Efforts to Ensure Proper Use of Prazaxa
August 29, 2011
- Remicade Obtains Approval for Partial Changes in Dosage for Crohn's Disease
August 29, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…